tiprankstipranks
Trending News
More News >
CanBas Co., Ltd. (JP:4575)
:4575
Japanese Market

CanBas Co., Ltd. (4575) Price & Analysis

Compare
0 Followers

4575 Stock Chart & Stats

¥787.00
-¥23.00(-2.48%)
At close: 4:00 PM EST
¥787.00
-¥23.00(-2.48%)

4575 FAQ

What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥739.00 and its highest was ¥1558.00 in the past 12 months.
    What is CanBas Co., Ltd.’s market cap?
    CanBas Co., Ltd.’s market cap is ¥16.50B.
      When is CanBas Co., Ltd.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were CanBas Co., Ltd.’s earnings last quarter?
      Currently, no data Available
      Is CanBas Co., Ltd. overvalued?
      According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does CanBas Co., Ltd. pay dividends?
        CanBas Co., Ltd. does not currently pay dividends.
        What is CanBas Co., Ltd.’s EPS estimate?
        CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does CanBas Co., Ltd. have?
        CanBas Co., Ltd. has 19,713,655 shares outstanding.
          What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of CanBas Co., Ltd.?
          Currently, no hedge funds are holding shares in JP:4575
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            CanBas Co., Ltd.

            CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

            CanBas Co., Ltd. (4575) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Healios KK
            StemRIM Inc.
            Renascience Inc.
            Japan Tissue Engineering Co., Ltd.
            CellSeed Inc.
            Popular Stocks